LPTX – Leap Therapeutics Inc
Float Short %
7.11
Margin Of Safety %
Put/Call OI Ratio
EPS Next Q Diff
0.2
EPS Last/This Y
0.7
EPS This/Next Y
0.58
Price
2.05
Target Price
5.5
Analyst Recom
3
Performance Q
741.54
Relative Volume
219.54
Beta
0.09
Ticker: LPTX
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-12-09 | LPTX | 2.05 | N/A | N/A | 0 |
| 2025-12-10 | LPTX | 2.05 | N/A | N/A | 0 |
| 2025-12-11 | LPTX | 2.05 | N/A | N/A | 0 |
| 2025-12-12 | LPTX | 2.05 | N/A | N/A | 0 |
| 2025-12-15 | LPTX | 2.05 | N/A | N/A | 0 |
| 2025-12-16 | LPTX | 2.05 | N/A | N/A | 0 |
| 2025-12-17 | LPTX | 2.05 | N/A | N/A | 0 |
| 2025-12-18 | LPTX | 2.05 | N/A | N/A | 0 |
| 2025-12-19 | LPTX | 2.05 | N/A | N/A | 0 |
| 2025-12-22 | LPTX | 2.05 | N/A | N/A | 0 |
| 2025-12-23 | LPTX | 2.05 | N/A | N/A | 0 |
| 2025-12-26 | LPTX | 2.05 | N/A | N/A | 0 |
| 2025-12-29 | LPTX | 2.05 | N/A | N/A | 0 |
| 2025-12-30 | LPTX | 2.05 | N/A | N/A | 0 |
| 2025-12-31 | LPTX | 2.05 | N/A | N/A | 0 |
| 2026-01-02 | LPTX | 2.05 | N/A | N/A | 0 |
| 2026-01-05 | LPTX | 2.05 | N/A | N/A | 0 |
| 2026-01-06 | LPTX | 2.05 | N/A | N/A | 0 |
| 2026-01-07 | LPTX | 2.05 | N/A | N/A | 0 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
No data found
No data found
Last Quarter Act. EPS
-0.4
Avg. EPS Est. Current Quarter
-0.24
Avg. EPS Est. Next Quarter
-0.2
Insider Transactions
Institutional Transactions
-5.11
Beta
0.09
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
4
Growth Score
19
Sentiment Score
88
Actual DrawDown %
95.1
Max Drawdown 5-Year %
-99.4
Target Price
5.5
P/E
Forward P/E
PEG
P/S
P/B
14.86
P/Free Cash Flow
EPS
-1.59
Average EPS Est. Cur. Y
-1.11
EPS Next Y. (Est.)
-0.53
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
219.54
Return on Equity vs Sector %
-1175.7
Return on Equity vs Industry %
-1160.9
EPS 1 7Days Diff
0.1
EPS 1 30Days Diff
0.15
EBIT Estimation
Leap Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 52
Cypherpunk Technologies Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer. The company also develops FL-501, a monoclonal antibody that inhibits GDF-15 protein that is in preclinical trial. It has an option and license agreement with Adimab, LLC and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as Leap Therapeutics, Inc. and changed its name to Cypherpunk Technologies Inc. in November 2025. The company was incorporated in 2011 and is based in Cambridge, Massachusetts.
stock quote shares LPTX – Leap Therapeutics Inc Stock Price stock today
news today LPTX – Leap Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch LPTX – Leap Therapeutics Inc yahoo finance google finance
stock history LPTX – Leap Therapeutics Inc invest stock market
stock prices LPTX premarket after hours
ticker LPTX fair value insiders trading